A consultant who specializes in helping Chinese biosimilar companies market their products in the European Union discusses the challenges and opportunities.
Jenny Hao, pharma operating partner with Convergence Partners, is a biosimilars consultant who spoke recently at the Terrapinn Festival of Biologics meeting in Basel, Switzerland. In this video, she speaks with Tony Hagen, senior editor for The Center for Biosimilars® about the interest Chinese biosimilars producers have in Europe and the challenges they face. The prospects for biosimilar sales in China are huge, but there are many companies in the market battling for share, and so they are slowly turning in the direction of sales abroad, including the European Union, she explains. However, in entering the European Union they must go up against many large and well-established biopharmaceutical companies. Ultimately, market share will go to the most efficient and economical producers, Hao says.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.